Terms: = Head and neck cancer AND Neurokinin
22 results:
1. Targeting the Nerve-cancer Circuit.
Ye Y; Xie T; Amit M
Cancer Res; 2023 Aug; 83(15):2445-2447. PubMed ID: 37470842
[TBL] [Abstract] [Full Text] [Related]
2. Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin‑1 receptor.
Zheng Y; Sang M; Liu F; Gu L; Li J; Wu Y; Shan B
Oncol Rep; 2023 Jul; 50(1):. PubMed ID: 37203393
[TBL] [Abstract] [Full Text] [Related]
3. Immunolocalization of neurokinin 1 receptor in WHO grade 4 astrocytomas, oral squamous cell and urothelial carcinoma.
Mehboob R; Kurdi M; Baeesa S; Fawzy Halawa T; Tanvir I; Maghrabi Y; Hakamy S; Saeedi R; Moshref R; Nasief H; Hassan A; Waseem H; Rasool S; Bahakeem B; Faizo E; Katib Y; Bamaga A; Aldardeir N
Folia Neuropathol; 2022; 60(2):165-176. PubMed ID: 35950469
[TBL] [Abstract] [Full Text] [Related]
4. Substance P and neurokinin 1 Receptor in Chronic Inflammation and cancer of the head and neck: A Review of the Literature.
Esteban F; Ramos-García P; Muñoz M; González-Moles MÁ
Int J Environ Res Public Health; 2021 Dec; 19(1):. PubMed ID: 35010633
[TBL] [Abstract] [Full Text] [Related]
5. Aprepitant Promotes Caspase-Dependent Apoptotic Cell Death and G2/M Arrest through PI3K/Akt/NF-
Javid H; Afshari AR; Zahedi Avval F; Asadi J; Hashemy SI
Biomed Res Int; 2021; 2021():8808214. PubMed ID: 34926694
[TBL] [Abstract] [Full Text] [Related]
6. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression.
Mohammadi F; Javid H; Afshari AR; Mashkani B; Hashemy SI
Mol Biol Rep; 2020 Jun; 47(6):4263-4272. PubMed ID: 32436041
[TBL] [Abstract] [Full Text] [Related]
7. The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study.
Isorna I; Esteban F; Solanellas J; Coveñas R; Muñoz M
Eur J Histochem; 2020 Apr; 64(2):. PubMed ID: 32363847
[TBL] [Abstract] [Full Text] [Related]
8. The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-κB signal transduction pathways.
Javid H; Asadi J; Zahedi Avval F; Afshari AR; Hashemy SI
Mol Biol Rep; 2020 Mar; 47(3):2253-2263. PubMed ID: 32072401
[TBL] [Abstract] [Full Text] [Related]
9. SP promotes cell proliferation in esophageal squamous cell carcinoma through the NK1R/Hes1 axis.
Wang F; Liu S; Liu J; Feng F; Guo Y; Zhang W; Zheng G; Wang Q; Cai L; Guo M; Lian X; Xu G; Zhang H
Biochem Biophys Res Commun; 2019 Jul; 514(4):1210-1216. PubMed ID: 31109645
[TBL] [Abstract] [Full Text] [Related]
10. Cost-minimization analysis of GSTP1c.313A>G genotyping for the prevention of cisplatin-induced nausea and vomiting: A Bayesian inference approach.
Macedo LT; Ferrari VE; Carron J; Costa EFD; Lopes-Aguiar L; Lourenço GJ; Lima CSP
PLoS One; 2019; 14(3):e0213929. PubMed ID: 30870506
[TBL] [Abstract] [Full Text] [Related]
11. Role of neurokinin 3 Receptor Signaling in Oral Squamous Cell Carcinoma.
Obata K; Shimo T; Okui T; Matsumoto K; Takada H; Takabatake K; Kunisada Y; Ibaragi S; Yoshioka N; Kishimoto K; Nagatsuka H; Sasaki A
Anticancer Res; 2017 Nov; 37(11):6119-6123. PubMed ID: 29061792
[TBL] [Abstract] [Full Text] [Related]
12. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.
Song JS; Tawa M; Chau NG; Kupper TS; LeBoeuf NR
BMC Cancer; 2017 Mar; 17(1):200. PubMed ID: 28302100
[TBL] [Abstract] [Full Text] [Related]
13. Addition of the neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
Jahn F; Riesner A; Jahn P; Sieker F; Vordermark D; Jordan K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1101-1107. PubMed ID: 26059352
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy.
Ishimaru K; Takano A; Katsura M; Yamaguchi N; Kaneko K; Takahashi H
Asian Pac J Cancer Prev; 2014; 15(22):9627-30. PubMed ID: 25520079
[TBL] [Abstract] [Full Text] [Related]
15. Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas.
Tsukahara K; Nakamura K; Motohashi R; Sato H; Endo M; Katsube Y; Ueda Y; Suzuki M
Acta Otolaryngol; 2014 Nov; 134(11):1198-204. PubMed ID: 25315920
[TBL] [Abstract] [Full Text] [Related]
16. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Longo F; Mansueto G; Lapadula V; De Sanctis R; Quadrini S; Grande R; Gori B; Altavilla A; D'Antoni I; Del Signore E; Stumbo L; De Luca C; Cimadon B; Cortesi E; Gamucci T; Di Seri M
Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
[TBL] [Abstract] [Full Text] [Related]
17. A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma.
Brener S; González-Moles MA; Tostes D; Esteban F; Gil-Montoya JA; Ruiz-Avila I; Bravo M; Muñoz M
Anticancer Res; 2009 Jun; 29(6):2323-9. PubMed ID: 19528498
[TBL] [Abstract] [Full Text] [Related]
18. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2.
Muñoz M; Rosso M; Aguilar FJ; González-Moles MA; Redondo M; Esteban F
Invest New Drugs; 2008 Apr; 26(2):111-8. PubMed ID: 17906845
[TBL] [Abstract] [Full Text] [Related]
19. Decreased neuropeptide release may play a role in the pathogenesis of nasal polyps.
Gungor A; Baroody FM; Naclerio RM; White SR; Corey JP
Otolaryngol Head Neck Surg; 1999 Nov; 121(5):585-90. PubMed ID: 10547475
[TBL] [Abstract] [Full Text] [Related]
20. Regulatory peptides and other neuroendocrine markers in medullary carcinoma of the thyroid.
Hanna FW; Ardill JE; Johnston CF; Cunningham RT; Curry WJ; Russell CF; Buchanan KD
J Endocrinol; 1997 Feb; 152(2):275-81. PubMed ID: 9071985
[TBL] [Abstract] [Full Text] [Related]
[Next]
